<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Nephrology Now &#187; Vasculitis</title>
	<atom:link href="http://www.nephrologynow.com/publications/category/vasculitis/feed" rel="self" type="application/rss+xml" />
	<link>http://www.nephrologynow.com</link>
	<description></description>
	<lastBuildDate>Tue, 20 Jul 2010 07:46:28 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<script type="text/javascript">

if (typeof Meebo == 'undefined') {

Meebo=function(){(Meebo._=Meebo._||[]).push(arguments)};
(function(q){

	var args = arguments;
	if (!document.body) { return setTimeout(function(){ args.callee.apply(this, args) }, 100); }
	var d=document, b=d.body, m=b.insertBefore(d.createElement('div'), b.firstChild); s=d.createElement('script');
	m.id='meebo'; m.style.display='none'; m.innerHTML='<iframe id="meebo-iframe"></iframe>';
	s.src='http'+(q.https?'s':'')+'://'+(q.stage?'stage-':'')+'cim.meebo.com/cim/cim.php?network='+q.network;
	b.insertBefore(s, b.firstChild);

})({network:'nephrologynow_bi16va'});	}</script>	<item>
		<title>Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis</title>
		<link>http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis#comments</comments>
		<pubDate>Tue, 20 Jul 2010 07:46:28 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[Acute Renal Failure]]></category>
		<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1547</guid>
		<description><![CDATA[
This RCT did not find that a rituximab-based regimen was superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis.

Related Articles:

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.


]]></description>
			<content:encoded><![CDATA[<div>
<div>This RCT did not find that a rituximab-based regimen was superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis.</div>
</div>
<p><strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis" rel="bookmark" title="July 20, 2010">Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis</a></li>
<li><a href="http://www.nephrologynow.com/publications/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-antineutrophil-cytoplasmic-antibody%e2%80%94associated-vasculitis" rel="bookmark" title="May 2, 2009">Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.</a></li>
<li><a href="http://www.nephrologynow.com/publications/mycophenolate-mofetil-versus-cyclophosphamide-for-induction-treatment-of-lupus-nephritis" rel="bookmark" title="May 2, 2009">Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.</a></li>
</ul>
<p><!-- Similar Posts took 9.565 ms --></p>
<img style='display:none' id="post-1547-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis',title:'Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis',tweet:' This RCT did not find that a rituximab-based regimen was superior to standard intravenous cyclophos',description:' This RCT did not find that a rituximab-based regimen was superior to standard intravenous cyclophos'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis</title>
		<link>http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis#comments</comments>
		<pubDate>Tue, 20 Jul 2010 07:45:22 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[Acute Renal Failure]]></category>
		<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com/?p=1544</guid>
		<description><![CDATA[This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
See the associated editorial.
Related Articles:

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
A Randomized, Doubleblind, Placebo-Controlled, [...]]]></description>
			<content:encoded><![CDATA[<div>This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.<br />
See the <a href="http://content.nejm.org/cgi/content/short/363/3/285 ">associated editorial</a>.</div>
<p><strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis" rel="bookmark" title="July 20, 2010">Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis</a></li>
<li><a href="http://www.nephrologynow.com/publications/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-antineutrophil-cytoplasmic-antibody%e2%80%94associated-vasculitis" rel="bookmark" title="May 2, 2009">Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.</a></li>
<li><a href="http://www.nephrologynow.com/publications/a-randomized-doubleblind-placebo-controlled-study-of-single-dose-rituximab-as-induction-in-renal-transplantation" rel="bookmark" title="July 6, 2009">A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation</a></li>
</ul>
<p><!-- Similar Posts took 7.537 ms --></p>
<img style='display:none' id="post-1544-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis',title:'Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis',tweet:'This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide t',description:'This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide t'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.</title>
		<link>http://www.nephrologynow.com/publications/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-antineutrophil-cytoplasmic-antibody%e2%80%94associated-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-antineutrophil-cytoplasmic-antibody%e2%80%94associated-vasculitis#comments</comments>
		<pubDate>Sat, 02 May 2009 22:24:06 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/?p=832</guid>
		<description><![CDATA[This randomized controlled trial compared pulse versus oral cyclophosphamide for induction in ANCA vasculitis. No difference in efficacy was detected between the two arms but pulse treatment resulted in a reduced cumulative cyclophosphamide dose and caused fewer cases of leukopenia.Related Articles:

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Rituximab [...]]]></description>
			<content:encoded><![CDATA[<p>This randomized controlled trial compared pulse versus oral cyclophosphamide for induction in ANCA vasculitis. No difference in efficacy was detected between the two arms but pulse treatment resulted in a reduced cumulative cyclophosphamide dose and caused fewer cases of leukopenia.<strong>Related Articles:</strong>
<ul class="similar-posts">
<li><a href="http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis" rel="bookmark" title="July 20, 2010">Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis</a></li>
<li><a href="http://www.nephrologynow.com/publications/mycophenolate-mofetil-versus-cyclophosphamide-for-induction-treatment-of-lupus-nephritis" rel="bookmark" title="May 2, 2009">Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.</a></li>
<li><a href="http://www.nephrologynow.com/publications/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis" rel="bookmark" title="July 20, 2010">Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis</a></li>
</ul>
<p><!-- Similar Posts took 8.142 ms --></p>
<img style='display:none' id="post-832-blankimage" onload="Meebo('discoverSharable', {element: ((this.parentNode.className.match('post')) ? this.parentNode : this.parentNode.parentNode) ,url:'http://www.nephrologynow.com/publications/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-antineutrophil-cytoplasmic-antibody%e2%80%94associated-vasculitis',title:'Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.',tweet:'This randomized controlled trial compared pulse versus oral cyclophosphamide for induction in ANCA v',description:'This randomized controlled trial compared pulse versus oral cyclophosphamide for induction in ANCA v'})"><script type='text/javascript'></script>]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-antineutrophil-cytoplasmic-antibody%e2%80%94associated-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?</title>
		<link>http://www.nephrologynow.com/publications/vasculitis-syndromes-which-maintenance-therapy-for-anca-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/vasculitis-syndromes-which-maintenance-therapy-for-anca-vasculitis#comments</comments>
		<pubDate>Fri, 01 May 2009 21:22:25 +0000</pubDate>
		<dc:creator>Nephrology Now editors</dc:creator>
				<category><![CDATA[Review]]></category>
		<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/vasculitis-syndromes-which-maintenance-therapy-for-anca-vasculitis</guid>
		<description><![CDATA[Related Articles:

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis


]]></description>
			<content:encoded><![CDATA[Related Articles:

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/vasculitis-syndromes-which-maintenance-therapy-for-anca-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Review article: Progress of treatment in ANCA-associated vasculitis.</title>
		<link>http://www.nephrologynow.com/publications/review-article-progress-of-treatment-in-anca-associated-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/review-article-progress-of-treatment-in-anca-associated-vasculitis#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/review-article-progress-of-treatment-in-anca-associated-vasculitis</guid>
		<description><![CDATA[Related Articles:

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis


]]></description>
			<content:encoded><![CDATA[Related Articles:

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/review-article-progress-of-treatment-in-anca-associated-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.</title>
		<link>http://www.nephrologynow.com/publications/outcomes-from-studies-of-antineutrophil-cytoplasm-antibody-associated-vasculitis-a-systematic-review-by-the-european-league-against-rheumatism-systemic-vasculitis-task-force</link>
		<comments>http://www.nephrologynow.com/publications/outcomes-from-studies-of-antineutrophil-cytoplasm-antibody-associated-vasculitis-a-systematic-review-by-the-european-league-against-rheumatism-systemic-vasculitis-task-force#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/outcomes-from-studies-of-antineutrophil-cytoplasm-antibody-associated-vasculitis-a-systematic-review-by-the-european-league-against-rheumatism-systemic-vasculitis-task-force</guid>
		<description><![CDATA[Related Articles:

Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review.
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?


]]></description>
			<content:encoded><![CDATA[Related Articles:

Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review.
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/outcomes-from-studies-of-antineutrophil-cytoplasm-antibody-associated-vasculitis-a-systematic-review-by-the-european-league-against-rheumatism-systemic-vasculitis-task-force/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Treatment for renal vasculitis and Goodpasture&#8217;s disease in adults.</title>
		<link>http://www.nephrologynow.com/publications/treatment-for-renal-vasculitis-and-goodpastures-disease-in-adults</link>
		<comments>http://www.nephrologynow.com/publications/treatment-for-renal-vasculitis-and-goodpastures-disease-in-adults#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/treatment-for-renal-vasculitis-and-goodpastures-disease-in-adults</guid>
		<description><![CDATA[Related Articles:

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.


]]></description>
			<content:encoded><![CDATA[Related Articles:

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/treatment-for-renal-vasculitis-and-goodpastures-disease-in-adults/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.</title>
		<link>http://www.nephrologynow.com/publications/mycophenolate-mofetil-versus-cyclophosphamide-for-inducing-remission-of-anca-vasculitis-with-moderate-renal-involvement</link>
		<comments>http://www.nephrologynow.com/publications/mycophenolate-mofetil-versus-cyclophosphamide-for-inducing-remission-of-anca-vasculitis-with-moderate-renal-involvement#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/mycophenolate-mofetil-versus-cyclophosphamide-for-inducing-remission-of-anca-vasculitis-with-moderate-renal-involvement</guid>
		<description><![CDATA[Related Articles:

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis


]]></description>
			<content:encoded><![CDATA[Related Articles:

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/mycophenolate-mofetil-versus-cyclophosphamide-for-inducing-remission-of-anca-vasculitis-with-moderate-renal-involvement/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Challenges in the management of microscopic polyangiitis: past, present and future.</title>
		<link>http://www.nephrologynow.com/publications/challenges-in-the-management-of-microscopic-polyangiitis-past-present-and-future</link>
		<comments>http://www.nephrologynow.com/publications/challenges-in-the-management-of-microscopic-polyangiitis-past-present-and-future#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/challenges-in-the-management-of-microscopic-polyangiitis-past-present-and-future</guid>
		<description><![CDATA[Related Articles:

Urine proteomics: the present and future of measuring urinary protein components in disease.
The advantages and challenges of increasing the duration and frequency of maintenance dialysis sessions.
Preeclampsia&#8211;a glimpse into the future?


]]></description>
			<content:encoded><![CDATA[Related Articles:

Urine proteomics: the present and future of measuring urinary protein components in disease.
The advantages and challenges of increasing the duration and frequency of maintenance dialysis sessions.
Preeclampsia&#8211;a glimpse into the future?


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/challenges-in-the-management-of-microscopic-polyangiitis-past-present-and-future/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.</title>
		<link>http://www.nephrologynow.com/publications/treatment-of-hepatitis-c-associated-mixed-cryoglobulinemia-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/treatment-of-hepatitis-c-associated-mixed-cryoglobulinemia-vasculitis#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/treatment-of-hepatitis-c-associated-mixed-cryoglobulinemia-vasculitis</guid>
		<description><![CDATA[Related Articles:

Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil.
Review article: Progress of treatment in ANCA-associated vasculitis.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil.
Review article: Progress of treatment in ANCA-associated vasculitis.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/treatment-of-hepatitis-c-associated-mixed-cryoglobulinemia-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.</title>
		<link>http://www.nephrologynow.com/publications/bsr-and-bhpr-guidelines-for-the-management-of-adults-with-anca-associated-vasculitis</link>
		<comments>http://www.nephrologynow.com/publications/bsr-and-bhpr-guidelines-for-the-management-of-adults-with-anca-associated-vasculitis#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/bsr-and-bhpr-guidelines-for-the-management-of-adults-with-anca-associated-vasculitis</guid>
		<description><![CDATA[Related Articles:

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Guidelines for the management of chronic kidney disease.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Guidelines for the management of chronic kidney disease.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/bsr-and-bhpr-guidelines-for-the-management-of-adults-with-anca-associated-vasculitis/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review.</title>
		<link>http://www.nephrologynow.com/publications/treatment-of-antineutrophil-cytoplasmic-antibody-associated-vasculitis-a-systematic-review</link>
		<comments>http://www.nephrologynow.com/publications/treatment-of-antineutrophil-cytoplasmic-antibody-associated-vasculitis-a-systematic-review#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/treatment-of-antineutrophil-cytoplasmic-antibody-associated-vasculitis-a-systematic-review</guid>
		<description><![CDATA[Related Articles:

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Antineutrophil Cytoplasmic Autoantibody–Negative Pauci-immune Crescentic Glomerulonephritis.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Antineutrophil Cytoplasmic Autoantibody–Negative Pauci-immune Crescentic Glomerulonephritis.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/treatment-of-antineutrophil-cytoplasmic-antibody-associated-vasculitis-a-systematic-review/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arterial Microaneurysms in Polyarteritis Nodosa.</title>
		<link>http://www.nephrologynow.com/publications/arterial-microaneurysms-in-polyarteritis-nodosa</link>
		<comments>http://www.nephrologynow.com/publications/arterial-microaneurysms-in-polyarteritis-nodosa#comments</comments>
		<pubDate>Tue, 30 Nov 1999 05:00:00 +0000</pubDate>
		<dc:creator>editor</dc:creator>
				<category><![CDATA[Vasculitis]]></category>

		<guid isPermaLink="false">http://www.nephrologynow.com.s65750.gridserver.com/publications/arterial-microaneurysms-in-polyarteritis-nodosa</guid>
		<description><![CDATA[Related Articles:

Calciphylaxis with Arterial Calcification
Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada.
Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study.


]]></description>
			<content:encoded><![CDATA[Related Articles:

Calciphylaxis with Arterial Calcification
Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada.
Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study.


]]></content:encoded>
			<wfw:commentRss>http://www.nephrologynow.com/publications/arterial-microaneurysms-in-polyarteritis-nodosa/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
